GRIFOLS S A/S (NASDAQ:GRFS) and Fibrocell Science (NASDAQ:FCSC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.
GRIFOLS S A/S pays an annual dividend of $0.39 per share and has a dividend yield of 1.8%. Fibrocell Science does not pay a dividend. GRIFOLS S A/S pays out 35.5% of its earnings in the form of a dividend.
GRIFOLS S A/S has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Fibrocell Science has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.
This table compares GRIFOLS S A/S and Fibrocell Science’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|GRIFOLS S A/S||16.55%||18.32%||6.24%|
Earnings & Valuation
This table compares GRIFOLS S A/S and Fibrocell Science’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|GRIFOLS S A/S||$4.88 billion||2.96||$749.04 million||$1.10||19.25|
|Fibrocell Science||$350,000.00||56.92||-$16.24 million||($8.25)||-0.26|
GRIFOLS S A/S has higher revenue and earnings than Fibrocell Science. Fibrocell Science is trading at a lower price-to-earnings ratio than GRIFOLS S A/S, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations for GRIFOLS S A/S and Fibrocell Science, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|GRIFOLS S A/S||2||3||2||0||2.00|
GRIFOLS S A/S currently has a consensus price target of $20.00, suggesting a potential downside of 5.57%. Fibrocell Science has a consensus price target of $16.00, suggesting a potential upside of 647.66%. Given Fibrocell Science’s stronger consensus rating and higher probable upside, analysts plainly believe Fibrocell Science is more favorable than GRIFOLS S A/S.
Institutional and Insider Ownership
21.4% of GRIFOLS S A/S shares are owned by institutional investors. Comparatively, 25.9% of Fibrocell Science shares are owned by institutional investors. 1.2% of Fibrocell Science shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
GRIFOLS S A/S beats Fibrocell Science on 9 of the 16 factors compared between the two stocks.
GRIFOLS S A/S Company Profile
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Fibrocell Science Company Profile
Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.